American Association for Cancer Research
Browse
21598290cd130096-sup-supp_fig_2.pdf (177.62 kB)

Supplementary Figure from Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic Transformation

Download (177.62 kB)
journal contribution
posted on 2023-04-03, 20:50 authored by Jin Xu, Kevin M. Haigis, Ari J. Firestone, Megan E. McNerney, Qing Li, Elizabeth Davis, Shann-Ching Chen, Joy Nakitandwe, James Downing, Tyler Jacks, Michelle M. Le Beau, Kevin Shannon

Supplementary Figure 2 - PDF file 177K, Data showing survival and Hematologic Parameters of Nras heterozygous, hemizygous and homozygous mice

History

ARTICLE ABSTRACT

Biochemical properties of Ras oncoproteins and their transforming ability strongly support a dominant mechanism of action in tumorigenesis. However, genetic studies unexpectedly suggested that wild-type (WT) Ras exerts tumor suppressor activity. Expressing oncogenic NrasG12D in the hematopoietic compartment of mice induces an aggressive myeloproliferative neoplasm that is exacerbated in homozygous mutant animals. Here, we show that increased NrasG12D gene dosage, but not inactivation of WT Nras, underlies the aggressive in vivo behavior of NrasG12D/G12D hematopoietic cells. Modulating NrasG12D dosage had discrete effects on myeloid progenitor growth, signal transduction, and sensitivity to MAP-ERK kinase (MEK) inhibition. Furthermore, enforced WT N-Ras expression neither suppressed the growth of Nras-mutant cells nor inhibited myeloid transformation by exogenous NrasG12D. Importantly, NRAS expression increased in human cancer cell lines with NRAS mutations. These data have therapeutic implications and support reconsidering the proposed tumor suppressor activity of WT Ras in other cancers.Significance: Understanding the mechanisms of Ras-induced transformation and adaptive cellular responses is fundamental. The observation that oncogenic Nras lacks tumor suppressor activity, whereas increased dosage strongly modulates cell growth and alters sensitivity to MEK inhibition, suggests new therapeutic opportunities in cancer. Cancer Discov; 3(9); 993–1001. ©2013 AACR.This article is highlighted in the In This Issue feature, p. 953